Business Description
Pentixapharm Holding AG
ISIN : DE000A40AEG0
Total Employee Number:
61Description
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.78 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.17 | |||||
Beneish M-Score | -3.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 58.7 | |||||
3-Year EBITDA Growth Rate | -186.8 | |||||
3-Year EPS without NRI Growth Rate | -103.2 | |||||
3-Year FCF Growth Rate | -43.8 | |||||
3-Year Book Growth Rate | -3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.04 | |||||
9-Day RSI | 47.48 | |||||
14-Day RSI | 48.16 | |||||
3-1 Month Momentum % | 24.31 | |||||
6-1 Month Momentum % | 50 | |||||
12-1 Month Momentum % | 5.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.15 | |||||
Quick Ratio | 2.15 | |||||
Cash Ratio | 1.75 | |||||
Days Sales Outstanding | 118.38 | |||||
Days Payable | 103.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -5.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -8135.14 | |||||
Operating Margin % | -24982.43 | |||||
Net Margin % | -21187.84 | |||||
EBITDA Margin % | -20029.73 | |||||
FCF Margin % | -20571.62 | |||||
OCF Margin % | -20544.59 | |||||
ROE % | -41.18 | |||||
ROA % | -33.7 | |||||
ROIC % | -41.44 | |||||
3-Year ROIIC % | 91.37 | |||||
ROC (Joel Greenblatt) % | -11296.34 | |||||
ROCE % | -43.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 733.33 | |||||
PB Ratio | 1.7 | |||||
Price-to-Tangible-Book | 73.33 | |||||
EV-to-EBIT | -2.66 | |||||
EV-to-EBITDA | -3.33 | |||||
EV-to-Revenue | 667.03 | |||||
EV-to-FCF | -3.24 | |||||
Earnings Yield (Greenblatt) % | -37.59 | |||||
FCF Yield % | -27.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pentixapharm Holding AG Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.074 | ||
| EPS (TTM) (€) | -0.64 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 49.28 | ||
| 14-Day RSI | 48.16 | ||
| 14-Day ATR (€) | 0.10934 | ||
| 20-Day SMA (€) | 2.3285 | ||
| 12-1 Month Momentum % | 5.14 | ||
| 52-Week Range (€) | 1.312 - 3.67 | ||
| Shares Outstanding (Mil) | 24.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pentixapharm Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pentixapharm Holding AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pentixapharm Holding AG Frequently Asked Questions
What is Pentixapharm Holding AG(FRA:PTP)'s stock price today?
The current price of FRA:PTP is €2.20. The 52 week high of FRA:PTP is €3.67 and 52 week low is €1.31.
When is next earnings date of Pentixapharm Holding AG(FRA:PTP)?
The next earnings date of Pentixapharm Holding AG(FRA:PTP) is .
Does Pentixapharm Holding AG(FRA:PTP) pay dividends? If so, how much?
Pentixapharm Holding AG(FRA:PTP) does not pay dividend.
Press Release
Articles on Pentixapharm Holding AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers